Cassava Sciences, Inc.
Investors that purchased the Company’s securities and have suffered a loss, please fill in transaction information below, or email to firstname.lastname@example.org.
There is no cost or obligation associated with submitting your information. If you are a shareholder who suffered a loss, please submit your contact information and purchase information to participate in the putative class action.
We also encourage you to contact Lesley F. Portnoy of The Portnoy Law Firm, at 310.692.8883, to discuss your rights free of charge. You can also reach us through the firm’s website at www.portnoylaw.com, or by email at email@example.com.
If you choose to take no action, you can remain an absent class member.
Joining the case through the Portnoy Law website enables investors to learn about their legal claims and take an active role in recovering their losses.
The Portnoy Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
Portnoy Law Firm
Lesley F. Portnoy, Esq.,
1800 Century Park East, Suite 600
Los Angeles, CA 90067
The investigation focuses on whether Cassava issued misleading and/or false statements and/or failed to disclose information pertinent to investors. Cassava announced supposedly positive results from a clinical trial of simufilam for treatment of Alzheimer’s patients. On July 30, 2021, despite Cassava’s claims, health industry news site STAT published concerns of scientists not affiliated with the study, describing the results as “overblown” and “uninterpretable.” A citizen petition was submitted to the FDA on August 18, 2021, calling on the agency to halt ongoing studies of simufilam until such time as the agency could verify the data already submitted by Cassava. The petition identifies alleged “errors and anomalies” in Cassava’s data “of a sufficient frequency and magnitude to strongly suggest scientific misconduct.” On August 25, 2021, shares of Cassava fell by more than 31%, based on this news.